HC Wainwright & Co. Downgrades NovoCure to Neutral, Announces $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar has downgraded NovoCure (NASDAQ:NVCR) from Buy to Neutral and set a price target of $25.
August 28, 2023 | 2:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NovoCure has been downgraded from Buy to Neutral by HC Wainwright & Co. with a new price target of $25.
The downgrade from Buy to Neutral by HC Wainwright & Co. indicates a less optimistic outlook for NovoCure. The new price target of $25 may also suggest that the analyst believes the stock is currently overvalued. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100